RASolute 302 Trial at ASCO 2026 Plennary Session: Daraxonrasib Improves Survival Versus Chemotherapy in Previously Treated Metastatic PDAC
oncodaily - RASolute 302 Trial was presented by Brian M. Wolpin, MD, MPH, during the 2026 ASCO Annual Meeting.The Trial evaluated daraxonrasib, an oral RAS(ON) multi-selective inhibitor, against investigator’s choice chemotherapy in […]
AI Summary: A plenary ASCO presentation reports daraxonrasib, an oral KRAS G12C inhibitor, significantly improved overall survival compared with chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. The data prompted immediate planning across cancer centers for anticipated demand and access changes — a rare dose of good news for a disease that usually gets none.
Related Stories
Daraxonrasib’s ASCO moment sparks rapid clinical uptake for pancreatic cancer / 2 months
FDA grants early access to experimental pancreatic cancer drug / 3 months
ENZAMET trial confirms long-term survival benefit of enzalutamide in mHSPC / 8 days
Map of daraxonrasib resistance points to combo strategies in pancreatic cancer / 15 days
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 1 month
Teclistamab shows survival benefit prompting earlier use discussions / 2 months
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 4 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Supply Chain, Infant Health, Healthcare, Pfizer and look for the RSS link.
StackHealth Time Machine